International Journal of Innovative Science and Research Technology (IJISRT)· 2026· Review
Repurposing Retatrutide for Neuroprotection in Parkinson’s Disease: A Comprehensive Review
- 0citations
- 2026year
Short summary
Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, shows promise for neuroprotection in Parkinson's disease by influencing neuronal survival, reducing inflammation, and enhancing mitochondrial function.
AI-generated from the title and abstract; the full text is not read.
Key points
- Parkinson's disease involves dopaminergic neuron loss, mitochondrial dysfunction, and impaired glucose metabolism.
- Retatrutide is a new triple agonist targeting GLP-1, GIP, and glucagon receptors.
- Activation of these receptors impacts neuronal survival, inflammation, and mitochondrial function.
- Preclinical studies with incretin-based therapies show reduced neurodegeneration and improved motor function in Parkinson's models.
AI-generated from the title and abstract; the full text is not read.
Abstract
Parkinson's disease is a progressive neurodegenerative condition marked by the loss of dopaminergic neurons, mitochondrial dysfunction, oxidative stress, and persistent neuroinflammation. Recent findings suggest that impaired glucose metabolism and disrupted energy balance may play a role in the early stages of the disease's progression. In light of this, therapies based on metabolic hormones have garnered interest for their potential neuroprotective effects. Retatrutide, a new triple agonist that targets GLP-1, GIP, and glucagon receptors, offers a promising therapeutic approach. The activation of these receptors influences crucial intracellular pathways that are involved in neuronal survival, reducing inflammation, and enhancing mitochondrial function. Preclinical research on incretin-based therapies has shown a decrease in dopaminergic neurodegeneration and improvements in motor function. This review delves into the impact of metabolic dysfunction in Parkinson’s disease and assesses the therapeutic promise of multi-receptor agonists, with a particular focus on Retatrutide. Although the findings are encouraging, additional clinical studies are necessary to confirm its effectiveness and safety in neurodegenerative diseases.
The authors' abstract, as published at the source. International Journal of Innovative Science and Research Technology (IJISRT), 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Neurology (Medicine)
NeurologyMedicine